RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

RBC Capital analyst Trung Huynh has reiterated an 'Outperform' rating on AbbVie (NYSE: ABBV) while maintaining a price target of $280. This re-evaluation suggests confidence in AbbVie's performance in the market.